Instil Bio
58 hedge funds and large institutions have $34.3M invested in Instil Bio in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 23 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.07% less ownership
Funds ownership: 3.16% → 3.08% (-0.07%)
6% less funds holding
Funds holding: 62 → 58 (-4)
24% less capital invested
Capital invested by funds: $45.3M → $34.3M (-$10.9M)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
57% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$504K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$329K |
| 3 |
Barclays
London,
United Kingdom
|
+$178K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$62.4K |
| 5 |
IC
IEQ Capital
Foster City,
California
|
+$60.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$985K |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$287K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$203K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$158K |
| 5 |
Two Sigma Advisers
New York
|
-$120K |
TIL Hedge Fund Activity: Q3 2023 in Review
58 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q3 2023, worth a combined $34.3M — down 24% from $45.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TIL and 9 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 10 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $504K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $985K sold.
- 58 institutional investors held Instil Bio (TIL) as of Q3 2023, down from 62 in Q2 2023.
- Funds reported $34.3M of Instil Bio stock for Q3 2023, down 24% quarter-over-quarter.
- 9 funds opened new Instil Bio positions in Q3 2023 and 13 closed out, a net change of -4 holders.
- The largest Instil Bio buyer in Q3 2023 was Nantahala Capital Management, an estimated $504K added.
- The largest Instil Bio seller in Q3 2023 was Samsara BioCapital, an estimated $985K sold.
Based on aggregated 13F filings for Q3 2023.